Links & Summaries to 7 New Articles on Hepatitis C

[Guest guest]

Vertex takes early rounds of hep C bout with Merck

EmpowHer

(Reuters) - In the bout between a pair of breakthrough hepatitis C treatments,

Incivek from upstart biotech Vertex Pharmaceuticals appears to have taken the

first round from pharmaceutical heavyweight Merck & Co and its Victrelis by a

wide margin. ...

See all stories on this topic »Mallory-Denk Bodies on Biopsy Predict Fibrosis

Progression in HCV

Internal Medicine News Digital Network

In patients who have chronic hepatitis C and undergo liver biopsy, the presence

of Mallory-Denk bodies – hepatocyte cytoplasmic inclusions that occur in several

chronic liver diseases – is independently associated with progression of liver

fibrosis, ...

See all stories on this topic » Defense attorney challenging ruling on Desai's

competency

Las Vegas Review - Journal

By Jeff German Defense attorney is seeking a hearing to challenge

the conclusions of the state medical experts who found Dr. Dipak Desai competent

to stand trial on criminal charges in the hepatitis C outbreak. ...

See all stories on this topic »

Medivir Announces Acceptance of Four TMC435 Abstracts for Presentation at the

....

MarketWatch (press release)

Medivir AB (omx:MVIR), a research-based speciality pharmaceutical company

focused on infectious diseases, today announces that four abstracts related to

its once daily (QD), oral investigational hepatitis C drug TMC435 have been

accepted for ...

See all stories on this topic »Hepatitis C in the US May Be Underestimated by

Over a Million

AIDSmeds.com HIV/AIDS Treatment News

In the United States, the number of people who have been infected with hepatitis

C virus (HCV) may have been undercounted by a whopping 1.1 million, according to

a paper published in the September 2011 edition of Liver International. ...

See all stories on this topic »Pharmasset Shares Surge on New Hep C Data

TheStreet.com

By Adam Feuerstein 09/30/11 - 11:09 AM EDT PRINCETON, NJ (TheStreet)

--Pharmasset(VRUS) shares are surging Friday after new data were released

bolstering the prospects for the company's Hepatitis C drug candidate PSI-7977.

Ten patients treated with an ...

See all stories on this topic »

Vertex to Present New Data from Hepatitis C Development Program at AASLD ...

MarketWatch (press release)

Additionally, new data from a Phase 2 study evaluating INCIVEK combination

treatment in people co-infected with genotype 1 chronic hepatitis C and human

immunodeficiency virus (HIV) will be presented at the meeting. All people in

this study were new to ...

See all stories on this topic »